Get the Stockscreener App
9.19
0.88%
0.08
After Hours:
9.25
0.06
+0.65%
Adma Biologics Inc stock is traded at $9.19, with a volume of 6.12M.
It is up +0.88% in the last 24 hours and down -44.57% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$9.11
Open:
$8.9
24h Volume:
6.12M
Relative Volume:
1.29
Market Cap:
$2.19B
Revenue:
$510.17M
Net Income/Loss:
$146.93M
P/E Ratio:
15.34
EPS:
0.599
Net Cash Flow:
$27.51M
1W Performance:
+10.86%
1M Performance:
-44.57%
6M Performance:
-36.75%
1Y Performance:
-54.57%
1-Day Range:
$8.80
$9.255
1-Week Range:
$8.80
$9.805
52-Week Range:
$7.2101
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.19 | 2.19B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA PE Ratio & Valuation, Is ADMA Overvalued - Intellectia AI
Stock Drop Alert: ADMA Biologics ($ADMA) Stock Plummets 29% after Channel Stuffing Claims DisclosedInvestors Notified of Securities Fraud Investigation - ACCESS Newswire
ADMA SEC FilingsAdma Biologics 10-K, 10-Q, 8-K Forms - Stock Titan
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc. - ACCESS Newswire
ADMA (ADMA) COO reports 20,362-share RSU tax withholding, holds 446,238 shares - Stock Titan
ADMA Biologics gains after refuting short seller claims - MSN
US High Growth Tech Stocks To Watch For Potential Expansion - Yahoo Finance Australia
ADMA Biologics Investigated for Securities Fraud After Plunge - National Today
Bronstein, Gewirtz & Grossman, LLC Encourages ADMA Biologics, Inc. (ADMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
$ADMA Stock News: ADMA Biologics Investigated for Securities Fraud Following Channel Stuffing Claims – Investors Notified to Contact BFA Law - GlobeNewswire Inc.
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Trading the Move, Not the Narrative: (ADMA) Edition - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADMA Biologics, Inc. (ADMA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ADMA Investor Alert: ADMA Biologics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Revenue Headwinds: Levi & Korsinsky - Sahm
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqui - The National Law Review
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation – ADMA - Eagle-Tribune
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026? - Zacks Investment Research
ADMA Biologics Under Investigation for Securities Fraud - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Investors to Reach Out - ACCESS Newswire
Investor Notice: ADMA Biologics ($ADMA) Stock Dropped 29% After Culper Research Report AnnouncementInvestigation Pending - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA ... - Bluefield Daily Telegraph
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential ... - Bluefield Daily Telegraph
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
ADMA Biologics Investigated for Securities Fraud After Stock Drop - National Today
ADMA Biologics Investigated for Securities Fraud After Plummeting Stock - National Today
ADMA Securities News: ADMA Biologics Investigated for Securities Fraud After Culper Research Report Revelation Sparks 29% Stock Drop - PR Newswire
Adma Biologics (ADMA) Shares Fall as Overall Market Rises: Key Insights for Investors - Bitget
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating - PR Newswire
2026-03-30 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Reach Out | NDAQ:ADMA | Press Release - Stockhouse
$ADMA Investor News: ADMA Biologics Faces Securities Fraud - globenewswire.com
ADMA Biologics (ADMA) soars 11.6% as firm denies short seller allegations - MSN
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
ADMA’s Upward Candlesticks Face Off Against a 41.6% Price Decline — What Lies Ahead? - Bitget
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect - ACCESS Newswire
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics, Inc. (ADMA) And Encourages Stockholders to Connect | NDAQ:ADMA | Press Release - Stockhouse
Did ADMA Biologics($ADMA) Mislead Investors about Channel Stuffing Issues? Investors with Losses Notified of Ongoing Securities Fraud Investigation - ACCESS Newswire
ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade) - Seeking Alpha
ADMA Biologics Faces Increased Short Interest Amid Allegations - National Today
ADMA Biologics Inc (NASDAQ:ADMA) Short Interest Update - MarketBeat
Does ADMA Biologics’ (ADMA) Rebuttal to Short-Seller Claims Strengthen Its Management Credibility Narrative? - Yahoo Finance
ADMA stock drops 6% after Culper Research alleges channel stuffing - msn.com
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
Is ADMA Biologics' (ADMA) Rebuttal of Short-Seller Claims a Crucial Test of Management Credibility? - Sahm
5 Stocks Investors Are Tracking Now - Insider Monkey
ADMA Biologics (ADMA) Soars 11.6% as Firm Denies Short Seller Allegations - Yahoo Finance
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - The National Law Review
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over - GlobeNewswire
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research - StreetInsider
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):